These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency. Hucke O; Coulombe R; Bonneau P; Bertrand-Laperle M; Brochu C; Gillard J; Joly MA; Landry S; Lepage O; Llinàs-Brunet M; Pesant M; Poirier M; Poirier M; McKercher G; Marquis M; Kukolj G; Beaulieu PL; Stammers TA J Med Chem; 2014 Mar; 57(5):1932-43. PubMed ID: 23773186 [TBL] [Abstract][Full Text] [Related]
26. Quinolones as HCV NS5B polymerase inhibitors. Kumar DV; Rai R; Brameld KA; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Shaghafi MB; Hu H; Lehoux I; To N; Young WB; Green MJ Bioorg Med Chem Lett; 2011 Jan; 21(1):82-7. PubMed ID: 21145235 [TBL] [Abstract][Full Text] [Related]
27. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623 [TBL] [Abstract][Full Text] [Related]
28. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives. Krueger AC; Madigan DL; Green BE; Hutchinson DK; Jiang WW; Kati WM; Liu Y; Maring CJ; Masse SV; McDaniel KF; Middleton TR; Mo H; Molla A; Montgomery DA; Ng TI; Kempf DJ Bioorg Med Chem Lett; 2007 Apr; 17(8):2289-92. PubMed ID: 17300933 [TBL] [Abstract][Full Text] [Related]
29. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. Zhao C; Wang Y; Ma S Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434 [TBL] [Abstract][Full Text] [Related]
30. Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization. Goulet S; Poupart MA; Gillard J; Poirier M; Kukolj G; Beaulieu PL Bioorg Med Chem Lett; 2010 Jan; 20(1):196-200. PubMed ID: 19945870 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B. Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484 [TBL] [Abstract][Full Text] [Related]
32. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671 [TBL] [Abstract][Full Text] [Related]
33. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956 [TBL] [Abstract][Full Text] [Related]
34. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Li LS; Zhou Y; Murphy DE; Stankovic N; Zhao J; Dragovich PS; Bertolini T; Sun Z; Ayida B; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Showalter RE; Patel R; Lebrun LA; Bartkowski DM; Nolan TG; Norris DA; Kamran R; Brooks J; Sergeeva MV; Kirkovsky L; Zhao Q; Kissinger CR Bioorg Med Chem Lett; 2008 Jun; 18(11):3446-55. PubMed ID: 18457949 [TBL] [Abstract][Full Text] [Related]
35. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465 [TBL] [Abstract][Full Text] [Related]
36. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003 [TBL] [Abstract][Full Text] [Related]
37. Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review. Xie Y; Ogah CA; Jiang X; Li J; Shen J Curr Drug Targets; 2016; 17(13):1560-76. PubMed ID: 26648061 [TBL] [Abstract][Full Text] [Related]
38. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Abdurakhmanov E; Øie Solbak S; Danielson UH Viruses; 2017 Jun; 9(6):. PubMed ID: 28621755 [TBL] [Abstract][Full Text] [Related]
39. Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. Beaulieu PL; Coulombe R; Duan J; Fazal G; Godbout C; Hucke O; Jakalian A; Joly MA; Lepage O; Llinàs-Brunet M; Naud J; Poirier M; Rioux N; Thavonekham B; Kukolj G; Stammers TA Bioorg Med Chem Lett; 2013 Jul; 23(14):4132-40. PubMed ID: 23768906 [TBL] [Abstract][Full Text] [Related]
40. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]